Half-year report · HY
4536.TEDINET S100X02E
Period2025-04-01 → 2025-09-30
Filed2025-11-10
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 47
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥137.9bn | 2025-04-01 → 2025-09-30 | Cons. | Revenue IFRS |
| Revenue | ¥300.0bn | 2024-04-01 → 2025-03-31 | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥146.4bn | 2024-04-01 → 2024-09-30 | Cons. | Revenue IFRS |
| Operating income | ¥17.9bn | 2025-04-01 → 2025-09-30 | Cons. | Operating profit loss IFRS |
| Operating income | ¥23.9bn | 2024-04-01 → 2024-09-30 | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥17.6bn | 2025-04-01 → 2025-09-30 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥47.5bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥23.8bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss before tax IFRS |
| Net income (owners) | ¥13.9bn | 2025-04-01 → 2025-09-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥36.3bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥18.8bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income | ¥13.9bn | 2025-04-01 → 2025-09-30 | Cons. | Profit loss IFRS |
| Net income | ¥18.7bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss IFRS |
| Total assets | ¥389.1bn | at 2025-09-30 | Cons. | Assets IFRS |
| Total assets | ¥409.3bn | at 2025-03-31 | Cons. | Assets IFRS |
| Total assets | ¥409.1bn | at 2024-09-30 | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥115.5bn | at 2025-09-30 | Cons. | Liabilities IFRS |
| Total liabilities | ¥124.1bn | at 2025-03-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥273.6bn | at 2025-09-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥285.2bn | at 2025-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥288.3bn | at 2024-09-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥305.4bn | at 2024-03-31v | Cons. | Equity IFRS |
| Equity (owners) | ¥274.8bn | at 2025-09-30 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥286.2bn | at 2025-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥289.0bn | at 2024-09-30 | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥63.6bn | at 2025-09-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥93.0bn | at 2025-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥84.4bn | at 2024-09-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥94.6bn | at 2024-03-31v | Cons. | Cash and cash equivalents IFRS |
| Operating cash flow | ¥13.6bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥60.9bn | 2024-04-01 → 2025-03-31 | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥28.3bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Investing cash flow | −¥9.6bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥8.2bn | 2024-04-01 → 2025-03-31 | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥4.5bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Financing cash flow | −¥36.0bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥53.3bn | 2024-04-01 → 2025-03-31 | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥32.2bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities IFRS |
| EPS (basic) | ¥41.76 | 2025-04-01 → 2025-09-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥103.98 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥52.88 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (diluted) | ¥41.7 | 2025-04-01 → 2025-09-30 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥103.68 | 2024-04-01 → 2025-03-31 | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥52.74 | 2024-04-01 → 2024-09-30 | Cons. | Diluted earnings loss per share IFRS |
| Equity ratio | 70.6% | at 2025-09-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 69.9% | at 2025-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 70.6% | at 2024-09-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
All source rows · 585
| Item | Context | Value | Unit |
|---|---|---|---|
| Purchase of intangible assets inv cf IFRS | Prior1InterimDuration | -1761000000 | JPY |
| Purchase of intangible assets inv cf IFRS | InterimDuration | -6049000000 | JPY |
| Other inv cf IFRS | Prior1InterimDuration | -37000000 | JPY |
| Other inv cf IFRS | InterimDuration | -32000000 | JPY |
| Net cash provided by used in investing activities IFRS | Prior1InterimDuration | -4478000000 | JPY |
| Net cash provided by used in investing activities IFRS | InterimDuration | -9572000000 | JPY |
| Repayments of long term borrowings fin cf IFRS | Prior1InterimDuration | -159000000 | JPY |
| Repayments of long term borrowings fin cf IFRS | InterimDuration | － | JPY |
| Payments for purchase of treasury shares fin cf IFRS | Prior1InterimDuration | -24370000000 | JPY |
| Payments for purchase of treasury shares fin cf IFRS | InterimDuration | -27793000000 | JPY |
| Dividends paid fin cf IFRS | Prior1InterimDuration | -6168000000 | JPY |
| Dividends paid fin cf IFRS | InterimDuration | -6479000000 | JPY |
| Repayments of lease obligations fin cf IFRS | Prior1InterimDuration | -1533000000 | JPY |
| Repayments of lease obligations fin cf IFRS | InterimDuration | -1695000000 | JPY |
| Other fin cf IFRS | Prior1InterimDuration | 0 | JPY |
| Other fin cf IFRS | InterimDuration | 2000000 | JPY |
| Net cash provided by used in financing activities IFRS | Prior1InterimDuration | -32229000000 | JPY |
| Net cash provided by used in financing activities IFRS | InterimDuration | -35964000000 | JPY |
| Net increase decrease in cash and cash equivalents before effect of exchange rate changes IFRS | Prior1InterimDuration | -8400000000 | JPY |
| Net increase decrease in cash and cash equivalents before effect of exchange rate changes IFRS | InterimDuration | -31963000000 | JPY |
| Cash and cash equivalents IFRS | Prior2YearInstant | 94582000000 | JPY |
| Cash and cash equivalents IFRS | Prior1YearInstant | 92997000000 | JPY |
| Effect of exchange rate changes on cash and cash equivalents IFRS | Prior1InterimDuration | -1740000000 | JPY |
| Effect of exchange rate changes on cash and cash equivalents IFRS | InterimDuration | 2526000000 | JPY |
| Cash and cash equivalents IFRS | Prior1InterimInstant | 84441000000 | JPY |
| Cash and cash equivalents IFRS | InterimInstant | 63560000000 | JPY |
| Document title cover page | FilingDateInstant | Original text (Japanese)半期報告書 | |
| Clause of stipulation cover page | FilingDateInstant | Original text (Japanese)金融商品取引法第24条の５第１項の表の第１号 | |
| Place of filing cover page | FilingDateInstant | Original text (Japanese)関東財務局長 | |
| Filing date cover page | FilingDateInstant | 2025-11-10 | |
| Semi annual accounting period cover page | FilingDateInstant | Original text (Japanese)第114期中（自 2025年４月１日 至 2025年９月30日） | |
| Company name cover page | FilingDateInstant | Original text (Japanese)参天製薬株式会社 | |
| Company name in english cover page | FilingDateInstant | SANTEN PHARMACEUTICAL CO., LTD. | |
| Title and name of representative cover page | FilingDateInstant | Original text (Japanese)代表取締役社長兼CEO 伊藤 毅 | |
| Address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)大阪府大阪市北区大深町４番20号 | |
| Telephone number address of registered headquarter cover page | FilingDateInstant | 06(4802)9322 | |
| Name of contact person address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)Head of Accounting and Tax, Japan高木 宏典 | |
| Nearest place of contact cover page | FilingDateInstant | Original text (Japanese)大阪府大阪市北区大深町４番20号 | |
| Telephone number nearest place of contact cover page | FilingDateInstant | 06(4802)9322 | |
| Name of contact person nearest place of contact cover page | FilingDateInstant | Original text (Japanese)Head of Accounting and Tax, Japan高木 宏典 | |
| Place for public inspection cover page (text) | FilingDateInstant | Text · Plus | |
| Edinet code | FilingDateInstant | E00949 | |
| Fund code | FilingDateInstant | － | |
| Security code | FilingDateInstant | 45360 | |
| Filer name in japanese | FilingDateInstant | Original text (Japanese)参天製薬株式会社 | |
| Filer name in english | FilingDateInstant | SANTEN PHARMACEUTICAL CO., LTD. | |
| Fund name in japanese | FilingDateInstant | － | |
| Fund name in english | FilingDateInstant | － | |
| Cabinet office ordinance | FilingDateInstant | Original text (Japanese)企業内容等の開示に関する内閣府令 | |
| Document type | FilingDateInstant | Original text (Japanese)第四号の三様式 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |